First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34788
Abstract: BACKGROUND E7130 is a novel anticancer agent created from a total synthetic study of norhalichondrin B. The authors report the E7130 dose-escalation part of a first-in-human study of patients with advanced solid tumors (NCT03444701). METHODS… read more here.
Keywords: dose escalation; group; escalation part; study ... See more keywords
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_144
Abstract: NHL. Interim data are reported here. Methods: Relapsed/refractory HL or NHL pts who have no available established therapies known to provide clinical benefit at their current disease state are being recruited to a dose escalation… read more here.
Keywords: relapsed refractory; part; response; dose escalation ... See more keywords
Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation?
Sign Up to like & getrecommendations! Published in 2017 at "Strahlentherapie und Onkologie"
DOI: 10.1007/s00066-017-1108-y
Abstract: BackgroundAfter lung-sparing radiotherapy for malignant pleural mesothelioma (MPM), local failure at sites of previous gross disease represents the dominant form of failure. Our aim is to investigate if selective irradiation of the gross pleural disease… read more here.
Keywords: von; mpm; irradiation; dose escalation ... See more keywords
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3540-9
Abstract: Combining sorafenib and eribulin mesylate may provide synergistic antitumor activities with limited overlapping toxicities. This phase 1b, open-label, dose-escalation study evaluated safety, pharmacokinetics, maximum tolerated dose/recommended phase 2 dose (MTD/RP2D), and preliminary efficacy of sorafenib… read more here.
Keywords: open label; dose escalation; phase open; label dose ... See more keywords
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3610-z
Abstract: PurposeTo determine the maximum tolerated dose (MTD) of BEZ235, an oral inhibitor of class I PI3K and mTOR complexes 1 and 2.MethodsWe performed a phase I/Ib, multicenter, open-label study of oral BEZ235 administered in a… read more here.
Keywords: pi3k mtor; dose escalation; bez235; study ... See more keywords
Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04202-0
Abstract: The ideal starting dose for an oncology first-in-patient (FIP) trial should be low enough to be safe but not too far removed from therapeutically relevant doses. A low starting dose combined with small dose increments… read more here.
Keywords: first patient; dose escalation; starting dose; small molecule ... See more keywords
Effect of SIB-IMRT-based selective dose escalation of local tumor on the prognosis of patients with esophageal cancer
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-01943-7
Abstract: To investigate the effect of SIB-IMRT-based selective dose escalation to local tumor on the prognosis of patients with esophageal cancer (EC). A total of 302 EC patients were enrolled. The prognostic factors of the entire… read more here.
Keywords: dose escalation; prognostic factors; escalation local; selective dose ... See more keywords
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
Sign Up to like & getrecommendations! Published in 2017 at "Investigational New Drugs"
DOI: 10.1007/s10637-017-0467-7
Abstract: SummaryBackground Voxtalisib, a PI3K/mTOR inhibitor, has shown antitumor activity in capsule formulation in patients with solid tumors. This Phase I study assessed safety and pharmacokinetics of voxtalisib administered as immediate-release tablets in patients with solid… read more here.
Keywords: solid tumors; dose escalation; voxtalisib; safety pharmacokinetics ... See more keywords
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-01054-6
Abstract: Background BI 836826 is a chimeric mouse–human monoclonal antibody directed against human CD37, a transmembrane protein expressed on mature B lymphocytes. This open-label, phase I dose-escalation trial (NCT02624492) was conducted to determine the maximum tolerated… read more here.
Keywords: relapsed refractory; 836826 combination; patients relapsed; dose escalation ... See more keywords
Does Proton Therapy Have a Future in CNS Tumors?
Sign Up to like & getrecommendations! Published in 2017 at "Current Treatment Options in Neurology"
DOI: 10.1007/s11940-017-0447-4
Abstract: Opinion statementProton therapy is characterized by certain physical properties leading to a reduction in integral dose. As proton therapy becomes more widely available, the ongoing discussion on the real indications for proton therapy becomes more… read more here.
Keywords: therapy; proton therapy; dose escalation; cns tumors ... See more keywords
Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
Sign Up to like & getrecommendations! Published in 2017 at "PharmacoEconomics"
DOI: 10.1007/s40273-017-0526-0
Abstract: ObjectivesThe aim of this study was to quantify the value of conducting additional research and reducing uncertainty regarding the cost effectiveness of allopurinol and febuxostat for the management of gout.MethodsWe used a previously developed Markov… read more here.
Keywords: information; dose escalation; study; value ... See more keywords